Anti-Toxoplasma Antibodies in Egyptian Rheumatoid Arthritis Patients

Overview

Journal Rheumatol Int

Specialty Rheumatology

Date 2017 Mar 22

PMID 28321492

Citations 4

Authors

Abeer A El-Henawy

Eman Abdel Razek Hafez

Nairmen Nabih

Naglaa M Shalaby

Mervat Mashaly

Affiliations

Soon will be listed here.

Abstract

Objective: To assess seroprevalence of anti-Toxoplasma gondii antibodies; both IgG and IgM in Egyptian rheumatoid arthritis (RA) patients versus a non-RA group and to compare anti-Toxoplasma antibodies seroprevalence among RA patients receiving traditional treatment and RA patients treated with biologic drug.

Methods: 60 RA patients and 60 healthy controls were enrolled in the study. Patients were categorized into two groups: one group included 30 patients receiving disease modifying anti-rheumatic drugs (DMARDs), while the other group included 30 patients receiving biologic agent, infliximab, a TNF-α antagonist. Serum samples of all investigated persons were examined for anti-Toxoplasma antibodies. RA activity markers including rheumatoid factor, anti-cyclic citrullinated protein antibodies, C reactive protein, ESR in addition to disease activity score 28 (DAS28) of RA patients were also evaluated to explore their association with Toxoplasma seropositivity.

Results: Anti-Toxoplasma IgG antibodies were detected among 46/60 RA patients (76.7%) versus 29/60 controls (48.3%), (p = 0.001). Anti-Toxoplasma IgG titre was higher among RA group [median, (range) = 232.940 (8.949-653.242) IU/ml] than among controls [median, (range) = 68.820 (2.450-318.945) IU/ml], (p < 0.001). No difference was detected among RA patients either on traditional or biologic treatment regarding anti-Toxoplasma IgG antibodies. No positive anti-Toxoplasma IgM was detected. A positive correlation was detected between anti-Toxoplasma IgG titre and disease activity markers.

Conclusion: Higher seroprevalence of anti-Toxoplasma IgG antibodies among RA patients compared to controls reflects an association between latent Toxoplasma infection and RA. Our findings support previous studies and necessitate future large-scale studies to elucidate the exact role of Toxoplasma whether a trigger of autoimmunity in RA or an effect of immunosuppression.

Citing Articles

Vaccination with Toxoplasma lysate antigen or its encapsulated niosomes form immunomodulates adjuvant-induced arthritis through JAK3 downregulation.

Hassouna S, Allam E, Sheta E, Khodear G, Khedr M, Khedr S Inflammopharmacology. 2023; 31(6):3101-3114.

PMID: 37389660 PMC: 10692027. DOI: 10.1007/s10787-023-01267-0.

and seropositivity in juvenile idiopathic arthritis and its relation to disease activity and type of therapies.

Salem D, Al-Ghamdi A, Alghamdi J, Ismail A, Alghamdi B, Abdelrazek E Food Waterborne Parasitol. 2023; 31:e00195.

PMID: 37256200 PMC: 10225886. DOI: 10.1016/j.fawpar.2023.e00195.

Toxoplasmosis seroprevalence in rheumatoid arthritis patients: A systematic review and meta-analysis.

Hosseininejad Z, Sharif M, Sarvi S, Amouei A, Hosseini S, Nayeri Chegeni T PLoS Negl Trop Dis. 2018; 12(6):e0006545.

PMID: 29870527 PMC: 6003687. DOI: 10.1371/journal.pntd.0006545.

Seroprevalence of Toxoplasma gondii infection in arthritis patients in eastern China.

Tian A, Gu Y, Zhou N, Cong W, Li G, Elsheikha H Infect Dis Poverty. 2017; 6(1):153.

PMID: 29065914 PMC: 5655948. DOI: 10.1186/s40249-017-0367-2.

References

Elsheikha H, Azab M, Abousamra N, Rahbar M, Elghannam D, Raafat D . Seroprevalence of and risk factors for Toxoplasma gondii antibodies among asymptomatic blood donors in Egypt. Parasitol Res. 2009; 104(6):1471-6. DOI: 10.1007/s00436-009-1350-z. View

Maini R, St Clair E, Breedveld F, Furst D, Kalden J, Weisman M . Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 2000; 354(9194):1932-9. DOI: 10.1016/s0140-6736(99)05246-0. View

Young J, McGwire B . Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med. 2005; 353(14):1530-1. DOI: 10.1056/NEJMc051556. View

Engman D, Leon J . Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop. 2002; 81(2):123-32. DOI: 10.1016/s0001-706x(01)00202-9. View

Toth P, Bernd R . Severe leukopenia in a rheumatoid arthritis patient treated with a methotrexate/leflunomide combination. Rev Bras Reumatol. 2014; 54(2):152-4. View

Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K . Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999; 130(6):478-86. DOI: 10.7326/0003-4819-130-6-199903160-00004. View

Nardone R, Zuccoli G, Brigo F, Trinka E, Golaszewski S . Cerebral toxoplasmosis following adalimumab treatment in rheumatoid arthritis. Rheumatology (Oxford). 2013; 53(2):284. DOI: 10.1093/rheumatology/ket364. View

Zaccone P, Burton O, Cooke A . Interplay of parasite-driven immune responses and autoimmunity. Trends Parasitol. 2007; 24(1):35-42. DOI: 10.1016/j.pt.2007.10.006. View

Fischer S, Agmon-Levin N, Shapira Y, Porat Katz B, Graell E, Cervera R . Toxoplasma gondii: bystander or cofactor in rheumatoid arthritis. Immunol Res. 2013; 56(2-3):287-92. DOI: 10.1007/s12026-013-8402-2. View

10.

van der Veen M, van der Heide A, Kruize A, Bijlsma J . Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate. Ann Rheum Dis. 1994; 53(4):224-8. PMC: 1005299. DOI: 10.1136/ard.53.4.224. View

11.

Weinblatt M, Keystone E, Furst D, Moreland L, Weisman M, Birbara C . Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003; 48(1):35-45. DOI: 10.1002/art.10697. View

12.

Sert M, Ozbek S, Paydas S, Yaman A . Is there any relationship between toxoplasma infection and reactive arthritis?. J Postgrad Med. 2007; 53(1):14-6. DOI: 10.4103/0022-3859.30321. View

13.

Shim H . One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med. 2011; 43(10):539-49. PMC: 3222815. DOI: 10.3858/emm.2011.43.10.063. View

14.

Wallis R, Broder M, Wong J, Lee A, Hoq L . Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis. 2005; 41 Suppl 3:S194-8. DOI: 10.1086/429996. View

15.

Deeming G, Collingwood J, Pemberton M . Methotrexate and oral ulceration. Br Dent J. 2005; 198(2):83-5. DOI: 10.1038/sj.bdj.4811972. View

16.

Xynos I, Tektonidou M, Pikazis D, Sipsas N . Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe. Emerg Infect Dis. 2009; 15(6):956-9. PMC: 2727307. DOI: 10.3201/eid1506.090101. View

17.

Azevedo V, Pietrovski C, de Almeida Santos Jr M . [Acute toxoplasmosis infection in a patient with ankylosing spondylitis treated with adalimumab: a case report]. Reumatismo. 2011; 62(4):283-5. DOI: 10.4081/reumatismo.2010.283. View

18.

Aletaha D, Neogi T, Silman A, Funovits J, Felson D, Bingham 3rd C . 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010; 62(9):2569-81. DOI: 10.1002/art.27584. View

19.

Lassoued S, Zabraniecki L, Marin F, Billey T . Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. Semin Arthritis Rheum. 2006; 36(4):262-3. DOI: 10.1016/j.semarthrit.2006.08.004. View

20.

Liesenfeld O, Kosek J, Remington J, Suzuki Y . Association of CD4+ T cell-dependent, interferon-gamma-mediated necrosis of the small intestine with genetic susceptibility of mice to peroral infection with Toxoplasma gondii. J Exp Med. 1996; 184(2):597-607. PMC: 2192709. DOI: 10.1084/jem.184.2.597. View